US stock movement: Arcutis surged on October 9 due to ZORYVE data and infant eczema news
Bitget异动解读2026/10/09 17:10Arcutis October 9 Surge Analysis
Keywords: ZORYVE data, infant eczema
1. On October 9, the company released data from the Phase II INTEGUMENT-INFANT trial of ZORYVE cream 0.05% in infants aged 3 to under 24 months with atopic dermatitis, showing that once-daily treatment achieved positive results, covering infant patients with limited treatment options.
2. On October 9, the company released new analyses from the ARRECTOR and DERMIS-1/2 trials, indicating that both ZORYVE cream and foam formulations can improve symptoms, skin clearance, and quality of life for patients with psoriasis, covering different areas of the body.
(Disclaimer: This content is generated by AI technology summarizing publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Microsoft CEO says AI has already been tested internally for event response scenarios
Microsoft (MSFT.US) CEO: We have tested its application internally at Microsoft in scenarios such as incident response, quality control, and scientific discovery.
Microsoft launches fast decision-making model Decision-1
Microsoft (MSFT.US) CEO: Launches Decision-1, a new model designed for rapid decision-making.
【US Stock Movement】Sezzle surged on October 9: Earnings forecast, BNPL demand, and subscription growth
